The 1993 guidelines for the management of mild hypertension: Memorandum from a WHO/ISH meeting

Blood Pressure

Volumn 2, Issue 2, 1993, Pages 86-100

  Zanchetti, A ^a   Chalmers, J P ^a   Arakawa, K ^a   Gyarfas, I ^a   Hamet, P ^a   Hansson, L ^a   Julius, S ^a   Macmahon, S ^a   Mancia, G ^a   Menard J ^a   Omae, T ^a   Reid, J ^a   Safar, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE; ANTIHYPERTENSIVE THERAPY; CLASSIFICATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPERTENSION; RISK FACTOR;

BLOOD PRESSURE; CLINICAL PROTOCOLS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMAN; HYPERTENSION; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 0027483749     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059309077535     Document Type: Article

References (51)

1. Blood pressure stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
2. Hypertension
3. Hypertension and the risk of cardiovascular disease
4. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
5. SHEP Cooperative Research Group
6. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
7. MRC Working Party
8. MRC Working Party
9. MRC Working Party on Mild to Moderate Hypertension
10. Alerting reaction and rise in blood pressure during measurement by physician and nurse
11. White coat hypertension: a follow-up
12. Ambulatory blood pressure monitoring: research and clinical applications
13. The British Hypertension Society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems
14. Ambulatory and home blood pressure normality: the PAMELA Study
15. Decision to treat mild hypertension after assessment by ambulatory monitoring and World Health Organization recommendations
16. What blood pressure level should be treated
17. Hypertension in the community
18. Report by the Management Committee
19. Medical Research Council Working Party
20. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context
21. WHO/ISH Guidelines Committee
22. Perspectives on systolic hypertension: the Framingham study
23. Fodor G for the Canadian Heart Health Surveys Research Group: prevalence control and awareness of high blood pressure among Canadian adults
24. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
25. WHO Expert Committee
26. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage
27. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
28. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
29. Prognostic value of serum creatinine and effect of treatment of hypertension in renal function
30. Clinical relevance of proteinuria and microalbuminuria in arterial hypertension
31. Prognosis in diabetic nephro-pathy
32. Benefits and potential harm of lowering high blood pressure
33. The HOT Study Group
34. All-cause mortality in the Hypertension Detection and Follow-up Program: findings in the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality
35. Cardiovascular effects of smoking
36. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study
37. Blood pressure changes: oestrogens in climateric women
38. Evaluation of organ damage in hypertension
39. Insulin resistance and cardiovascular drugs
40. Beta-blockade during and after myocardial infarction. An overview of the randomized trials
41. Angiotensin converting enzyme inhibition with captopril in human pregnancy
42. The SOLVD Investigators
43. The SOLVD Investigators
44. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial
45. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
46. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence
47. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies
48. For the SPRINT Study Group
49. Methyldopa
50. STOP-hypertension-2
51. Syst-Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives protocol and organization